Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes.

Panattoni, Laura; Brown, Paul M; Ao, Braden Te; Webster, Mark; Gladding, Patrick

Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes.

Panattoni, Laura; Brown, Paul M; Ao, Braden Te; Webster, Mark; Gladding, Patrick.

Afiliación

Panattoni L; School of Population Health, University of Auckland, Auckland, New Zealand. laura.e.panattoni@gmail.com.
Brown PM; Department of Health Policy Research, Palo Alto Medical Foundation Research Institute, 2350 W. El Camino Real, Mountain View, California, CA, 94040, USA. laura.e.panattoni@gmail.com.
Ao BT; School of Population Health, University of Auckland, Auckland, New Zealand.
Webster M; School of Social Sciences, Humanities and Arts, University of California, Merced, CA, USA.
Gladding P; School of Population Health, University of Auckland, Auckland, New Zealand.

Pharmacoeconomics ; 38(3): 315, 2020 Mar.

Article en En | MEDLINE | ID: mdl-31960352

ABSTRACT

ABSTRACT

Unfortunately, the article's Supplementary File Link is not working and the ESM material.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google